3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Interventions
Capecitabine
27
pembrolizumab
19
Oxaliplatin
19
Fluorouracil
17
Cisplatin
17
Trastuzumab
14
Docetaxel
14
Leucovorin
11
Paclitaxel
8
Irinotecan
8
S 1 (combination)
7
Epirubicin
6
Cyclophosphamide
5
tegafur-gimeracil-oteracil
4
aldesleukin
4
Hyperthermic Intraperitoneal Chemotherapy
4
titanium silicide
3
spartalizumab
3
fludarabine phosphate
3
fludarabine
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Ramucirumab
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
Ado-Trastuzumab Emtansine
3
vistusertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Stomach Neoplasms
×
rucaparib
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts